Immunome (IMNM) Projected to Post Earnings on Tuesday

Immunome (NASDAQ:IMNM - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $0.46 million for the quarter.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

IMNM stock traded up $0.06 during mid-day trading on Friday, reaching $7.77. 71,539 shares of the company's stock were exchanged, compared to its average volume of 910,290. Immunome has a 12-month low of $5.15 and a 12-month high of $16.81. The stock's 50 day moving average is $7.79 and its 200 day moving average is $9.99. The company has a market cap of $676.08 million, a price-to-earnings ratio of -0.96 and a beta of 2.00.

Insider Buying and Selling at Immunome

In other Immunome news, CTO Philip Tsai acquired 12,300 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the acquisition, the chief technology officer now owns 33,300 shares of the company's stock, valued at approximately $280,386. This trade represents a 58.57 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall bought 137,100 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the purchase, the chief executive officer now owns 806,736 shares in the company, valued at $5,881,105.44. This trade represents a 20.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 156,400 shares of company stock valued at $1,160,495 in the last three months. 8.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Wedbush reissued an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Lake Street Capital started coverage on Immunome in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price for the company. Finally, Guggenheim decreased their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $25.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.